Appetite and obesity: A gastroenterologist's perspective

Neurogastroenterology and Motility

Volumn 19, Issue 5, 2007, Pages 333-341

  Camilleri, M ^a   Grudell, A B M ^a  

^a MAYO CLINIC   (United States)

Author keywords

Appetite; Gastric emptying; Gastric volume; Obesity

Indexed keywords

AC 162325; ANOREXIGENIC AGENT; CANNABINOID RECEPTOR; CHOLECYSTOKININ; DRONABINOL; EXENDIN 4; GASTRIN; GHRELIN; GLUCAGON LIKE PEPTIDE 1; LEPTIN; LIRAGLUTIDE; NEUROPEPTIDE Y RECEPTOR; PEPTIDE YY; PRAMLINTIDE; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG;

APPETITE; BODY MASS; CLINICAL TRIAL; DIGESTION; DRUG EFFECT; FOOD INTAKE; GASTROINTESTINAL MOTILITY; GASTROPLASTY; HUMAN; HYPOTHALAMUS; LIPID ABSORPTION; NAUSEA; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; ROUX Y ANASTOMOSIS; SATIETY; STOMACH BYPASS; STOMACH EMPTYING; STOMACH FUNCTION; STOMACH PRESSURE; VAGUS NERVE; WEIGHT REDUCTION;

APPETITE; APPETITE REGULATION; EATING; GASTROENTEROLOGY; GASTROINTESTINAL HORMONES; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRACT; HUMANS; OBESITY; SATIATION;

EID: 34248524100     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2006.00864.x     Document Type: Review

References (64)

1. http://en.wikipedia.org/wiki/%22diamond_jim%22_brady. Wikipedia Foundation, Florida, USA.
2. Korner J, Leibel RL. To eat or not to eat - how the gut talks to the brain. N Engl J Med 2003 349: 926 8.
3. Horvath TL. Endocannabinoids and the regulation. J Clin Invest 2003 112: 323 6.
4. Huda MSB, Wilding JPH, Pinkney JH. Gut peptides and the regulation of appetite. Obes Rev 2006 7: 163 82.
5. Camilleri M. Integrated upper gastrointestinal response to food intake. Gastroenterology 2006 131: 640 58.
6. Hunt JN. Mechanisms and disorders of gastric emptying. Annu Rev Med 1983 34: 219 29.
7. Raybould HE, Meyer JH, Tabrizi Y, Liddle RA, Tso P. Inhibition of gastric emptying in response to intestinal lipid is dependent on chylomicron formation. Am J Physiol 1998 274: R1834 8.
8. Zhang JV, Ren PG, Avsian-Kretchmer O et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 2005 310: 996 9.
9. Batterham RL, Cohen MA, Ellis SM et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003 349: 941 8.
10. Cummings DE. Ghrelin and the short- and long-term regulation of appetite and body weight. Physiol Behav 2006 89: 71 84.
11. Korner J, Bessler M, Cirilo LJ et al. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab 2005 90: 359 65.
12. Kim BJ, Carlson OD, Jang HJ, Elahi D, Berry C, Egan JM. Peptide YY is secreted after oral glucose administration in a gender-specific manner. J Clin Endocrinol Metab 2005 90: 6665 71.
13. Alvarez Bartolome M, Borque M, Martinez-Sarmiento J et al. Peptide YY secretion in morbidly obese patients before and after vertical banded gastroplasty. Obes Surg 2002 12: 324 27.
14. Morinigo R, Moize V, Musri M et al. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2006 91: 1735 40.
15. Ockander L, Hedenbro JL, Rehfeld JF et al. Jejunoileal bypass changes the duodenal cholecystokinin and somatostatin cell density. Obes Surg 2003 13: 584 90.
16. Park MI, Camilleri M. Gastric motor and sensory functions in obesity. Obes Res 2005 13: 491 500.
17. Wright RA, Krinsky S, Fleeman C et al. Gastric emptying and obesity. Gastroenterology 1983 84: 747 51.
18. Horowitz M, Collins PJ, Cook DJ et al. Abnormalities of gastric emptying in obese patients. Int J Obes 1983 7: 415 21.
19. Horowitz M, Collins PJ, Shearman DJ. Effect of increasing the caloric/osmotic content of the liquid component of a mixed solid and liquid meal on gastric emptying in obese subjects. Hum Nutr Clin Nutr 1986 40: 51 6.
20. Zahorska-Markiewicz B, Jonderko K, Lelek A et al. Gastric emptying in obesity. Hum Nutr Clin Nutr 1986 40: 309 13.
21. Maddox A, Horowitz M, Wishart J et al. Gastric and esophageal emptying in obesity. Scand J Gastroenterol 1989: 24: 593 8.
22. Wisen O, Johansson C. Gastrointestinal function in obesity: motility secretion and absorption following a liquid test meal. Metabolism 1992 41: 390 95.
23. French SJ, Murray B, Rumsey RD et al. Preliminary studies on the gastrointestinal responses to fatty meals in obese people. Int J Obes Relat Metab Disord 1993 17: 295 300.
24. Glasbrenner B, Pieramico O, Brecht-Krauss D et al. Gastric emptying of solids and liquids in obesity. Clin Investig 1993 71: 542 6.
25. Huston WR, Wald A. Obesity and weight reduction do not influence gastric emptying and antral motility. Am J Gastroenterol 1993 88: 1405 9.
26. Corvilain B, Abramowicz M, Fery F et al. Effect of short-term starvation on gastric emptying in humans: relationship to oral glucose tolerance. Am J Physiol 1995 269: G512 7.
27. Portincasa P, Di Ciaula A, Palmieri V et al. Effects of cholestyramine on gallbladder and gastric emptying in obese and lean subjects. Eur J Clin Invest 1995 25: 746 53.
28. Tosetti C, Corinaldesi R, Stanghellini V et al. Gastric emptying of solids in morbid obesity. Int J Obes Relat Metab Disord 1996 20: 200 5.
29. Gryback P, Naslund E, Hellstrom PM et al. Gastric emptying of solids in humans: improved evaluation by Kaplan-Meier plots, with special reference to obesity and gender. Eur J Nucl Med 1996 23: 1562 7.
30. Verdich C, Madsen JL, Toubro S et al. Effect of obesity and major weight reduction on gastric emptying. Int J Obes Relat Metab Disord 2000 24: 899 905
31. Jackson SL, Leahy FE, McGowan AA et al. Delayed gastric emptying in the obese: an assessment using the non-invasive 13C-octanoic acid breath test. Diabetes Obes Metab 2004 6: 264 70.
32. Vazquez-Roque MI, Camilleri M, Stephens DA et al. Gastric sensorimotor functions and hormone profile in normal weight, overweight and obese people. Gastroenterology 2006 [Epub ahead of print].
33. Geliebter A, Hashim SA. Gastric capacity in normal, obese, and bulimic women. Physiol Behav 2001 74: 743 6.
34. Kim DY, Camilleri M, Murray JA, Stephens DA, Levine JA, Burton DD. Is there a role for gastric accommodation and satiety in asymptomatic obese people Obes Res 2001 9: 655 61.
35. Csendes A, Burgos AM. Size, volume and weight of the stomach in patients with morbid obesity compared to controls. Obes Surg 2005 15: 1133 6.
36. Tack J, Bisschops R. Mechanisms underlying meal-induced symptoms in functional dyspepsia. Gastroenterology 2004 127: 1844 7.
37. Feinle-Bisset C, Horowitz M. Dietary factors in functional dyspepsia. Neurogastroenterol Motil 2006 18: 608 18.
38. Delgado-Aros S, Camilleri M, Castillo EJ et al. Effect of gastric volume or emptying on meal-related symptoms after liquid nutrients in obesity: a pharmacologic study. Clin Gastroenterol Hepatol 2005 3: 997 1006.
39. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2004 3: CD004094.
40. Despres JP, Golay A, Sjostrom L, Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005 353: 2121 34.
41. Wadden TA, Berkowitz RI, Womble LG et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005 353: 2111 20.
42. Vazquez-Roque MI, Stephens D, Burton D et al. Sibutramine significantly delays gastric emptying without altering volume or postprandial symptoms in obesity. Gastroenterology 2006 130: A294.
43. Esfandyari T, Camilleri M, Ferber I, Burton D, Baxter K, Zinsmeister AR. Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects: a randomized, placebo-controlled study. Neurogastroenterol Motil 2006 18: 831 8.
44. Degen L, Oesch S, Casanova M et al. Effect of peptide YY3-36 on food intake in humans. Gastroenterology 2006 129: 1430 6.
45. Mathus-Vliegen EM, Tytgat GN. Intragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon-free follow-up. Gastrointest Endosc 2005 61: 19 27.
46. Neshev E, Onen D, Jalilian E, Mintchev MP. Pre-pyloric neural electrical stimulation produces cholinergically-mediated reverse peristalsis in the acute canine model of microprocessor-invoked gastric motility for the treatment of obesity. Obes Surg 2006 16: 510 20.
47. Xu X, Zhu H, Chen JD. Pyloric electrical stimulation reduces food intake by inhibiting gastric motility in dogs. Gastroenterology 2005 128: 43 50.
48. Liu J, Hou X, Song G, Cha H, Yang B, Chen JD. Gastric electrical stimulation using endoscopically placed mucosal electrodes reduces food intake in humans. Am J Gastroenterol 2006 101: 798 803.
49. Oesch S, Ruegg C, Fischer B, Degen L, Beglinger C. Effect of gastric distension prior to eating on food intake and feelings of satiety in humans. Physiol Behav 2006 87: 903 10.
50. O'Brien PE, Dixon JB, Laurie C et al. Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or an intensive medical program: a randomized trial. Ann Intern Med 2006 144: 625 33.
51. Sjostrom L, Lindroos AK, Peltonen M et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004 351: 2683 93.
52. Maggard MA, Shugarman LR, Suttorp M et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med 2005 142: 547 59.
53. Tack J, Depoortere I, Bisschops R et al. Influence of ghrelin on interdigestive gastrointestinal motility in humans. Gut 2006 55: 327 33.
54. Murray CD, Martin NM, Patterson M et al. Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. Gut 2005 54: 1693 8.
55. Levin F, Edholm T, Schmidt PT et al. Ghrelin stimulates gastric emptying and hunger in normal weight humans. J Clin Endocrinol Metab 2006 91: 3296 302.
56. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001 50: 1714 9.
57. Binn M, Albert C, Gougeon A et al. Effect of ghrelin on gastric emptying in patients with neurogenic gastroparesis. Gastroenterology 2005 101: A59.
58. Cremonini F, Camilleri M, Vazquez-Roque M et al. Obesity does not increase effects of synthetic ghrelin on human gastric motor functions. Gastroenterology 2006 131: 1431 9.
59. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S, RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005 365: 1389 97.
60. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006 295: 761 75.
61. Small CJ, Bloom SR. The therapeutic potential of gut hormone peptide YY3-36 in the treatment of obesity. Expert Opin Invest Drugs 2005 14: 647 53.
62. Delgado-Aros S, Kim D-Y, Burton DD et al. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested and postprandial symptoms in humans. Am J Physiol 2002 282: G424 31.
63. Samsom M, Szarka LA, Camilleri M, Vella A, Zinsmeister AR, Rizza RA. Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition. Am J Physiol 2000 278: G946 51.
64. Kopelman PG, Grace C. New thoughts on managing obesity. Gut 2004 53: 1044 53.